Loading...
XBRUTUB
Market cap6.38bUSD
Dec 20, Last price  
137.40EUR
1D
0.73%
1Q
3.62%
Jan 2017
131.63%
Name

Financiere de Tubize SA

Chart & Performance

D1W1MN
XBRU:TUB chart
P/E
69.38
P/S
—
EPS
1.98
Div Yield, %
0.63%
Shrs. gr., 5y
-0.02%
Rev. gr., 5y
5.42%
Revenues
0k
-100.00%
2,00000000000001,000302,000004,000008,1510
Net income
88m
-49.40%
123,907,000293,857,000477,274,00039,534,000-905,000163,308,00020,868,00064,685,00077,812,00061,706,00060,845,000212,526,000181,186,000285,934,000285,156,000-1,095,000260,519,000380,090,000174,225,31288,151,267
CFO
0k
-100.00%
3,051,000-12,838,000327,964,0005,605,0005,322,000-12,794,000-1,121,000124,000-1,404,000-823,000-613,00063,449,00067,699,00072,962,00075,757,00079,778,00081,138,00084,024,000174,225,3120
Dividend
Apr 30, 20240.97 EUR/sh
Earnings
Mar 22, 2025

Profile

Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
URL
http://www.financiere-tubize.be/
IPO date
Jan 02, 1987
Employees
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
8
 
Cost of revenue
2,078
1,882
2,029
Unusual Expense (Income)
NOPBT
(2,078)
(1,873)
(2,029)
NOPBT Margin
Operating Taxes
(89,055)
(119)
Tax Rate
NOPAT
(2,078)
87,182
(1,910)
Net income
88,151
-49.40%
174,225
-54.16%
380,090
45.90%
Dividends
(38,281)
(33,380)
(30,269)
Dividend yield
1.20%
1.06%
0.75%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
79,200
47,800
20,041
Long-term debt
Deferred revenue
453
117
Other long-term liabilities
Net debt
78,625
(1,790,956)
(1,739,080)
Cash flow
Cash from operating activities
174,225
84,024
CAPEX
Cash from investing activities
11,299
(5,713)
61,159
Cash from financing activities
(9,747)
(7,008)
(45,079)
FCF
2,928
124,996
(2,651)
Balance
Cash
575
1,069
15,900
Long term investments
1,837,687
1,743,221
Excess cash
575
1,838,756
1,759,121
Stockholders' equity
1,772,639
1,752,845
4,789,297
Invested Capital
1,876,155
46,999
1,507,746
ROIC
11.21%
ROCE
EV
Common stock shares outstanding
44,513
44,513
44,513
Price
71.70
1.27%
70.80
-21.59%
90.30
9.32%
Market cap
3,191,553
1.27%
3,151,492
-21.59%
4,019,488
9.32%
EV
3,270,178
1,360,536
2,280,408
EBITDA
(2,078)
(1,873)
(2,029)
EV/EBITDA
Interest
2,063
165
Interest/NOPBT